Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TN1N
|
|||
| Drug Name |
NY-ESO-TCR
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1/2 | [1] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1/2 | [1] | ||
| Myxoid round cell liposarcoma [ICD-11: 2B59] | Phase 1/2 | [1] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [1] | ||
| Synovial sarcoma [ICD-11: 2B5A; ICD-9: 171] | Phase 1/2 | [1] | ||
| Company |
Adaptimmune Philadelphia, PA GlaxoSmithKline Philadelphia, PA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell receptor (TCR) | Target Info | CAR-T-Cell-Therapy | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.